The Whitfield lab is currently working on several projects that are unified by genome-wide, systems biology approaches. The first is a translational project that uses genomic tools to study the systemic autoimmune disease scleroderma. The goal is to identify gene expression biomarkers that subset patients, predict clinical endpoints, and assess response to therapy. The second project utilizes microarrays and next generation ultrahigh-throughput sequencing to understand the regulation and gene function in the human cell division cycle. These projects are interconnected, as the 'proliferation signature' is a feature not only of cancer, but also of the scleroderma subsets.